GNI Group Ltd - ESG Rating & Company Profile powered by AI
Comprehensive Sustainability analysis of GNI Group Ltd can be accessed by signing up for free. This page displays a zero-cost Environmental, Social and Governance analysis covering GNI Group Ltd. The Disclosure score includes 17 UN Sustainable Development Goals including: 'No Poverty', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'.
GNI Group Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.5; made up of an environmental score of 0.0, social score of 0.0 and governance score of 1.6.
0.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1898 | Zota Health Care Ltd | 0.7 | Low |
| 1898 | cbdMD Inc | 0.7 | Low |
| 1924 | GNI Group Ltd | 0.5 | Low |
| 1924 | Beximco Pharmaceuticals Ltd | 0.5 | Low |
| 1924 | Acucela Inc | 0.5 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does GNI Group Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes GNI Group Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes GNI Group Ltd report the average age of the workforce?
Sign up for free to unlockDoes GNI Group Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes GNI Group Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes GNI Group Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes GNI Group Ltd offer flexible work?
Sign up for free to unlockDoes GNI Group Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes GNI Group Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes GNI Group Ltd conduct supply chain audits?
Sign up for free to unlockDoes GNI Group Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes GNI Group Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes GNI Group Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes GNI Group Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes GNI Group Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes GNI Group Ltd disclose water use targets?
Sign up for free to unlockDoes GNI Group Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid GNI Group Ltd have a product recall in the last two years?
Sign up for free to unlockDoes GNI Group Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes GNI Group Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas GNI Group Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes GNI Group Ltd disclose parental leave metrics?
Sign up for free to unlockDoes GNI Group Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes GNI Group Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes GNI Group Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes GNI Group Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes GNI Group Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes GNI Group Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs GNI Group Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes GNI Group Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes GNI Group Ltd disclose its waste policy?
Sign up for free to unlockDoes GNI Group Ltd report according to TCFD requirements?
Sign up for free to unlockDoes GNI Group Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes GNI Group Ltd disclose energy use targets?
Sign up for free to unlockDoes GNI Group Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes GNI Group Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for GNI Group Ltd
These potential risks are based on the size, segment and geographies of the company.
GNI Group Ltd. researches, develops, manufactures, and sells pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. The company provides Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary for the treatment of radiation pneumonitis, which is in pilot study for Phase III clinical trials; Tamibarotene, a product for treating acute promyelocytic leukemia; and F351 that is in Phase II clinical trial for the treatment of liver fibrosis. In addition, the company is developing Etuary for the treatment of diabetic nephropathy and connective tissue disease associated interstitial lung disease; and F573 for acute liver failure and acute-on-chronic liver failure. Further, it is developing diabetic nephropathy; and connective tissue disease associated interstitial lung disease, which are in investigational new drug application stage. GNI Group Ltd. was founded in 2001 and is headquartered in Tokyo, Japan.